Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069687 | 0.83 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2AUSP2HTT | |
| SCHEMBL29678765 | 0.83 | CYP1A2 (0.38) | MEN1KMT2AHPGDSMN1; SMN2ALOX15 | |
| SCHEMBL18305182 | 0.83 | CYP1A2 (0.38) | MEN1KMT2AHPGDSMN1; SMN2ALOX15 | |
| SCHEMBL5987150 | 0.81 | L3MBTL1 (0.38) | L3MBTL1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL25865672 | 0.81 | ALOX15 (0.35) | MEN1KMT2AMAPTATMHPGD | |
| SCHEMBL14742073 | 0.78 | TSHR (0.52) | MEN1KMT2ARAB9AHPGDSMN1; SMN2 | |
| SCHEMBL1866136 | 0.77 | KMT2A (0.48) | L3MBTL1MEN1KMT2AHTTMAPT | |
| SCHEMBL29831530 | 0.77 | KMT2A (0.48) | L3MBTL1MEN1KMT2AHTTMAPT | |
| SCHEMBL16855221 | 0.75 | TSHR (0.40) | MEN1KMT2AHTTMAPTHPGD | |
| SCHEMBL30364191 | 0.75 | TSHR (0.40) | MEN1KMT2AHTTMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4416143-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-4101852-A1 | PYRIDOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF | Bebetter Med Inc. (CN) | 2022-12-14 | — | — | EP | disclosed |
| US-20220389013-A1 | PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF | BEBETTER MED INC. (CN) | 2022-12-08 | — | — | US | disclosed |
| CN-112159405-B | Pyridopyrimidinone compounds and application thereof | 广州必贝特医药技术有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-112159405-A | Pyridopyrimidinone compounds and application thereof | 广州必贝特医药技术有限公司 | 2021-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389013-A1 | PYRIDOPYRIMIDINONE COMPOUNDS AND APPLICATIONS THEREOF | KRAS, NRAS, HRAS | L3MBTL1 4469/4885HTR1D 3791/4885MEN1 1880/4885 |
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | L3MBTL1 976/4885HTR1D 3820/4885MEN1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.